FDA approves Lilly’s EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis
EBGLYSS is now the only approved option that offers as few as six maintenance injections per year with…